 |
|
Nanoballs deliver drugs
October 25, 2007Dutch researcher Cristianne Rijcken has developed a new type of biodegradable nanoparticle. The spherical structures can encapsulate various fat-soluble medicines, which makes it easier to target tumour tissue. These nanoballs are highly promising carriers for the controlled release of anticancer drugs. Rijcken recently gained her doctorate for this research from Utrecht University.
Anticancer drugs sometimes have very harmful side effects because they do not distinguish between tumours and healthy tissue. However by encapsulating these drugs in nanoparticles, they more frequently end up in the right tissue. Due to the biodegradable nature of the nanoparticles, the drug is only released once the particles break down. The breakdown period can be adjusted by using different components for the nanostructures.
Drug packages
The nanoparticles consist of polyethylene glycol (PEG) chains which are attached to recently developed components: lactic acid derivatives of polymethacrylamides. These new chains possess the unique combined property of biodegradability and heat sensitivity. By simply heating up an aqueous polymer solution, compact spherical nanoparticles smaller than 100 nanometres are spontaneously formed. The properties and life span of Rijcken's so-called ' stabilised micelles' can be completely controlled by changing the components.
Experiments have shown that various types of fat-soluble anticancer drugs could be enclosed in the core of these micelles. The enclosed substances were only released after the lactic acid groups in the polymer had been split off, causing the nanoparticles to fall apart. The stabilised nanoballs accumulated to a larger extent in the tumours of tumour-carrying mice than traditional micelles. The new nanostructures exhibited no side effects and are completely biodegradable, whereas the current products with anticancer drugs often also contain other toxic ingredients.
Further research
Further research is needed to determine the blood circulation and tumour accumulation of drug-containing micelles. Additionally, the development of new components as building blocks for the nanoparticles will allow an even more accurate regulation of the specificity and drug release.
Netherlands Organization for Scientific Research
The nanoparticles consist of polyethylene glycol (PEG) chains which are attached to recently developed components: lactic acid derivatives of polymethacrylamides. These new chains possess the unique combined property of biodegradability and heat sensitivity. By simply heating up an aqueous polymer solution, compact spherical nanoparticles smaller than 100 nanometres are spontaneously formed. The properties and life span of Rijcken's so-called ' stabilised micelles' can be completely controlled by changing the components.
Experiments have shown that various types of fat-soluble anticancer drugs could be enclosed in the core of these micelles. The enclosed substances were only released after the lactic acid groups in the polymer had been split off, causing the nanoparticles to fall apart. The stabilised nanoballs accumulated to a larger extent in the tumours of tumour-carrying mice than traditional micelles. The new nanostructures exhibited no side effects and are completely biodegradable, whereas the current products with anticancer drugs often also contain other toxic ingredients.
Further research
Further research is needed to determine the blood circulation and tumour accumulation of drug-containing micelles. Additionally, the development of new components as building blocks for the nanoparticles will allow an even more accurate regulation of the specificity and drug release.
Netherlands Organization for Scientific Research
Anticancer Drug Current Events and Anticancer Drug News RSSNew type of fuel found in Patagonia fungus
A team led by a Montana State University professor has found a fungus that produces a new type of diesel fuel, which they say holds great promise.
Certain anticancer agents could be harmful to patients with heart disease
A set of promising new anticancer agents could have unforeseen risks in individuals with heart disease, suggests research at Washington University School of Medicine in St. Louis.
Gene mutation improves leukemia drug's effect
Gene mutations that make cells cancerous can sometimes also make them more sensitive to chemotherapy. A new study led by cancer researchers at Ohio State University shows that a mutation present in some cases of acute leukemia makes the disease more susceptible to high doses of a particular anticancer drug.
MIT researchers see alternative to common colorectal cancer drug
A compound that accumulates in cells more readily than a commonly used colorectal cancer drug may be just as useful in treating colorectal tumors, but with fewer side effects, MIT researchers have found.
Experimental anti-cancer synthetic molecule targets tumor cell growth and angiogenesis
A recent study conducted by three French CNRS (Centre National de la Recherche Scientifique) laboratories describes a new candidate anti-cancer drug, named HB-19.
Enzyme Structure Reveals New Drug Targets for Cancer and Other Diseases
If the genome is the parts list of the human cell, certain proteins are the production managers, activating and deactivating genes as needed. Scientists funded by the National Institute of General Medical Sciences (NIGMS), part of the National Institutes of Health, now have a clearer understanding of how a key protein controls gene activity and how mutations in the protein may cause disease.
Using evolution, UW team creates a template for many new therapeutic agents
By guiding an enzyme down a new evolutionary pathway, a team of University of Wisconsin-Madison researchers has created a new form of an enzyme capable of producing a range of potential new therapeutic agents with anticancer and antibiotic properties.
Carnegie Mellon scientists develop nanogels that enable controlled delivery of carbohydrate drugs
Carnegie Mellon University scientists have developed tiny, spherical nanogels that uniformly release encapsulated carbohydrate-based drugs.
Chemotherapy with bevacizumab increases risk of blood clots in arteries
Treatment with chemotherapy and bevacizumab, an anticancer drug, is associated with a greater risk of blood clots in patients' arteries compared with treatment with chemotherapy only.
UCLA researchers develop new nanomaterials to deliver anti-cancer drugs to cells
Researchers at UCLA have successfully manipulated nanomaterials to create a new drug-delivery system that promises to solve the challenge of the poor water solubility of today's most promising anticancer drugs and thereby increase their effectiveness.
More Anticancer Drug Current Events and Anticancer Drug News Articles
 | Medicinal Chemistry of Anticancer Drugs by Carmen Avendano, J. Carlos Menendez Antitumour chemotherapy is nowadays a very active field of research, and a huge amount of information on the topic is generated every year. Although many books are available that deal with clinical aspects of cancer chemotherapy, this book addresses the need for an updated treatment from the point of view of medicinal chemistry and drug design. Cytotoxic chemotherapy is gradually being... |
 | Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response (Cancer Drug Discovery and Development) The availability of new molecular approaches to the selection of drug therapy is an emerging need, as the traditional approach based on the evaluation of patient and tumor characteristics is clearly far from optimal. Many, and in most cases the majority of treated patients do not have significant benefits from the treatment while they often experience moderate to severe toxicities. In... |
 | Anticancer Drug Development Here in a single source is a complete spectrum of ideas on the development of new anticancer drugs. Containing concise reviews of multidisciplinary fields of research, this book offers a wealth of ideas on current and future molecular targets for drug design, including signal transduction, the cell division cycle, and programmed cell death. Detailed descriptions of sources for new drugs and... |
| Anticancer drug development: Proceedings of the 1st International Symposium on Management and Realization of Anticancer Drug Development, held in Granada, Spain on March 25-26, 1982 | |
 | Organ Directed Toxicities of Anticancer Drugs (Developments in Oncology) |
 | Anticancer Drug Toxicity: Prevention, Management, and Clinical Pharmacokinetics by Lipp Eberhard-Karls Univ., Tubingen, Germany. Offers analyses on the pharmacokinetic-pharmacodynamic and pharmacokinetic-toxicodynamic relationships of anticancer compounds. Explores therapeutic drug monitoring as a method of maximizing the efficacy, and minimizing the dangers, of chemotherapy. For clinicians, pharmacists, and... |
 | Novel Anticancer Drug Protocols (Methods in Molecular Medicine) Univ. of Tennessee, Memphis. Text provides a broad range of cutting-edge methodologies currently being used in the discovery and development of novel anti-cancer drugs. Discusses kinase inhibitor protocols, angiogenesis and metastasis protocols, and chaperoning/degradation protocols. For clinicians and... |
| Structure-Activity Relationship Analysis of Chinese Anticancer Drugs and Related Plants by Eric J. Lien | |
| FDA APPROVES LIGAND'S TARGRET CAPSULES FOR REFRACTORY CTCL.(Ligand Pharmaceuticals' anticancer drug): An article from: Biotech Business This digital document is an article from Biotech Business, published by Worldwide Videotex on February 1, 2000. The length of the article is 1748 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle:... | |
 | Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug 30 years after its discovery as an antitumor agent, cisplatin represents today one of the most successful drugs in chemotherapy. This book is intended to reminisce this event, to take inventory, and to point out new lines of development in this field. Divided in 6 sections and 22 chapters, the book provides an up-to-date account on topics such as - the chemistry and biochemistry of cisplatin, ... |
| © 2009 BrightSurf.com |